Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist cycles.
OBJECTIVE
To compare follicular fluid (FF) anti-Müllerian hormone (AMH) and inhibin B concentrations for GnRH agonist (GnRH-a) and GnRH antagonist cycles and to determine the correlations between FF AMH or inhibin B concentrations and controlled ovarian hyperstimulation (COH) outcomes.


METHODS
Prospective comparative study.


METHODS
University hospital.


METHODS
Eighty-seven women who underwent COH cycles, either in the GnRH-a long-protocol group (n = 43) or the GnRH antagonist multiple-dose flexible-protocol group (n = 44).


METHODS
Follicular fluid was obtained from dominant follicles during oocyte retrieval, and FF AMH, inhibin B, E(2), and P concentrations were measured. Serum levels of AMH and inhibin B also were assessed on the day of oocyte retrieval.


METHODS
Follicular fluid AMH and inhibin B concentrations.


RESULTS
Concentrations of serum AMH and inhibin B and of FF AMH, inhibin B, E(2), and P were similar in the two groups. Follicular fluid AMH levels were found to be significantly correlated with age, gonadotropin dose, number of follicles on hCG day, and number of oocytes retrieved.


CONCLUSIONS
Our results suggest that there is no significant difference in follicular microenvironment in terms of AMH and inhibin B secretion between GnRH-a and GnRH antagonist protocols and that FF AMH is a marker that reflects ovarian reserve and response to COH.
Lee
Jung Ryeol
JR
Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Seoul, Korea.
Kim
Seok Hyun
SH
Kim
Sun Mie
SM
Jee
Byung Chul
BC
Ku
Seung-Yup
SY
Suh
Chang Suk
CS
Choi
Young Min
YM
Kim
Jung Gu
JG
Moon
Shin Yong
SY
D000328:Adult; D000367:Age Factors; D054304:Anti-Mullerian Hormone / Q000097:blood / Q000378:metabolism*; D015415:Biomarkers / Q000378:metabolism; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D010064:Embryo Implantation; D004958:Estradiol / Q000378:metabolism; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage*; D005307:Fertilization in Vitro; D015571:Follicular Fluid / Q000187:drug effects* / Q000378:metabolism; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000819:agonists / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors; D006727:Hormone Antagonists / Q000008:administration & dosage*; D006801:Humans; D007247:Infertility, Female / Q000628:therapy; D007265:Inhibins / Q000097:blood / Q000378:metabolism*; D054315:Oocyte Retrieval; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D011374:Progesterone / Q000378:metabolism; D011446:Prospective Studies; D016896:Treatment Outcome; D017329:Triptorelin Pamoate / Q000008:administration & dosage*
D015415:Biomarkers; D006063:Chorionic Gonadotropin; D005300:Fertility Agents, Female; D006727:Hormone Antagonists; C422364:inhibin B; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D004958:Estradiol; D007265:Inhibins; D054304:Anti-Mullerian Hormone; C062876:cetrorelix